Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
In vivo CRISPR screen finds RASA2 and SOCS1 ablation enhanced T cell expansion in vitro; PTPN2, ZC3H12A and RC3H1 loss conferred early growth advantages in vivo; CDKN1B may be the most important factor limiting CAR T fitness late.”
Title: In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma
Authors: Nelson H. Knudsen, Giulia Escobar, Felix Korell, Tamina Kienka, Celeste Nobrega, Seth Anderson, Andrew Y. Cheng, Maria Zschummel, Alexander Armstrong, Amanda Bouffard, Michael C. Kann, Sadie Goncalves, Hans W. Pope, Mitra Pezeshki, Alexander Rojas, Juliette S. M. T. Suermondt, Merle Phillips, Trisha R. Berger, Sangwoo Park, Diego Salas-Benito, Elijah P. Darnell, Filippo Birocchi, Mark B. Leick, Rebecca C. Larson, John G. Doench, Debattama Sen, Kathleen B. Yates, Robert T. Manguso, Marcela V. Maus
You can read the Full Article in Nature.
You can find more posts featuring Robert Orlowski on OncoDaily.
